| Oct 29 |
Immutep Quarterly Activities Report Q1 FY25
|
| Oct 28 |
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
|
| Oct 17 |
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
|
| Oct 10 |
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
|
| Oct 7 |
Immutep: Navigating The Bumps In The Road
|
| Oct 4 |
Immutep concludes participant enrolment in Phase II breast cancer trial
|
| Oct 3 |
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
|
| Sep 24 |
Immutep receives A$3.6M R&D tax incentive from French government
|
| Sep 24 |
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
|
| Sep 18 |
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
|
